In anatomic, cytology and molecular practices, whether hospital-based or independent, the money leaks before a claim exists and again after the first payment posts.
Get a free revenue cycle assessmentPathology revenue cycle management is the whole financial path of a specimen: payer enrollment, eligibility, authorization, accessioning, charge capture, coding, claim submission, denial work, appeals, underpayment recovery and patient balances. Medical billing is one stage inside it. Pathology RCM starts before the specimen is grossed and ends when every dollar is reconciled.
A pathology group never meets the patient and never takes the order. Everything the claim needs arrives on a requisition filled in by someone else's front desk, hours before a courier collects it. If the ordering provider is wrong, the diagnosis missing or the plan lapsed last month, the lab finds out weeks later on a remittance.
The second difference is routing. One case can be billed three ways: globally to the payer, as a professional component when the specimen came from a hospital patient, or to the referring practice under a client-bill arrangement. The same slide is worth a different amount, owed by a different debtor, depending on where the tissue was taken.
The third is volume economics. Thousands of low-dollar cases a month means one point of clean claim rate is a five-figure problem and a manual appeal can cost more than the claim it rescues. And because the patient never chooses the pathologist, much of the commercial volume is out of network by construction, which puts statutory payment clocks inside the AR workflow.
Billing starts at the claim: code the case, submit it, post the payment. Our pathology billing services page covers that in code-level detail. The revenue cycle owns both sides of it, from payer enrollment and coverage checks before the specimen is grossed, through charge reconciliation against the accession log, to underpayment recovery months after the money lands.
Recognise three or more of these in your own numbers and the problem is the process, not the payer.
Get a free assessmentPathology sells on two axes: where the specimen came from, and who receives the bill. Both are settled before a code is chosen.
Every accession lands in one of three buckets: insurance bill, client bill to the referring practice, patient bill. A cycle built for one leaks on the other two, and the routing is decided at accessioning by whoever reads the requisition.
Searchers ask what the seven steps of the revenue cycle are. Here they are for pathology, with the failure mode that costs the most.
Every pathologist, the billing entity, the CLIA certificate and each referring client account has to exist in the payer's records first. Failure mode: a new pathologist reads for two months before enrollment is effective, and commercial plans allow no backdating.
Demographics, coverage, ordering provider and diagnosis arrive from a practice you do not control. Failure mode: coverage is checked after the case is resulted, when the only options left are a patient bill or a write-off.
Molecular testing needs commercial approval, and coverage-restricted tests a signed notice before the patient can be held liable. Failure mode: the test runs on clinical urgency and the approval never catches up.
The accession log is the only complete record of what the lab did. Failure mode: the case is read, signed and reported, no charge is created, and nothing downstream knows.
Specimens, stains, components and the date of service come from the signed report, and lab claims carry the performing lab's CLIA number. Failure mode: the claim leaves without it and rejects before adjudication. Our certified medical coders work from the signed report, not the requisition.
Remittances post, adjustments are written off, the account closes. Failure mode: the payer paid less than the contract says and the shortfall becomes permanent.
Denials are grouped by root cause, appealed with clinical support, and residual balances go to the patient in plain language. Failure mode: the appeal window passes while the claim sits in a queue. Our patient billing team owns it.
Pathology leaks where a claim scrubber cannot see: most of it happens before a claim exists or after one is paid. Dollars are annual, for a group signing out 4,000 cases a month at $92 net per case.
| Leak point | Codes or rule | What goes wrong | Annual dollars at risk | Luxen audit finding |
|---|---|---|---|---|
| Reading before enrollment is effective | Rule: 42 CFR 424.521 | Claims deny for a non-participating provider, past rescue once filing closes | $61,000 per pathologist added mid-year | Effective dates reconciled against the read-out roster monthly |
| Signed cases that never become a charge | CPT 88305, 88112 | Accession log and claim file never matched, so the case is read and never billed | $105,000 | 2.4% of signed accessions had no charge in the billing file 30 days after sign-out |
| Consults on slides prepared elsewhere | CPT 88321, 88323 | Consults sit in the LIS but outside the charge feed | $34,000 | Consults on slides prepared elsewhere were billed on 41% of the consults recorded in the LIS |
| Molecular tests resulted before coverage is confirmed | CPT 81479, PLA codes | Test runs, result reaches the clinician, denial arrives with nothing to appeal on | $78,000 | Commercial prior authorization on molecular pathology tests took a median 11 business days |
| Coverage-restricted tests with no signed notice | Form CMS-R-131, modifiers GA and GZ | The balance cannot move to the patient, and a GZ line denies with no liability | $23,000 | Necessity screening added at accessioning |
| Paid claims below the contracted rate | CPT 88342, 88361 | Remittances post at the paid amount, nothing checks the loaded fee schedule | $42,000 | Underpayments against contracted rates appeared on 7.8% of paid claims, short by $38 on average |
| Out-of-network claims left after the first payment | Rule: No Surprises Act open negotiation | First payment posts as final, the window closes, the dispute right expires | $56,000 | Every such claim worked to a written demand within 10 business days |
We will tell you which of these leaks is open in your practice, free, in 30 minutes.
Book the reviewEvery page on this subject names metrics. None publishes a number to hit. Typical is the federal figure where a federal file publishes one, named in the row, otherwise the median we measure at onboarding. Target is what Luxen holds pathology clients to (Luxen client data, 38 practices).
| Metric | Definition | Typical | Target |
|---|---|---|---|
| Days in AR | Receivables divided by average daily charges | 54 days at onboarding (Luxen client data) | 33 days by day 120 |
| Net collection rate | Payments divided by charges net of contractual adjustments | 91.4% at onboarding (Luxen client data) | 97.8% by month six |
| Clean claim rate | Claims accepted on first submission, no edit or rejection | 89.6% at onboarding (Luxen client data) | 97.3% by day 90 |
| First-pass denial rate | Share denied on first adjudication | 19% of in-network claims denied by HealthCare.gov issuers in 2024, all specialties (KFF analysis of the CMS Transparency in Coverage file) | Under 6% |
| Cost to collect | Cost of the revenue cycle divided by net collections | 7% to 9% billed in house (Luxen billing reviews) | 3% to 6% outsourced |
| Unbilled accession rate | Signed cases with no charge 30 days after sign-out | 2.4% across 34 pathology and laboratory practices (Luxen billing reviews) | Under 0.5% |
Typical values come from the named federal source in the table intro. Target values come from Luxen client data.
Original Medicare runs no prior authorization program covering anatomic pathology or clinical laboratory services, and the CMS WISeR model that began on 1 January 2026 in six states lists none of them. Authorization risk here is almost entirely commercial and almost entirely molecular: panels, hereditary cancer testing, tumor profiling and pharmacogenomics, several of which large plans route through a separate genetic testing vendor.
Commercial prior authorization on molecular pathology tests took a median 11 business days (Luxen claim audit), longer than most labs hold a specimen before running it. That gap is the problem: the test runs on urgency and the approval arrives, or does not, afterwards.
The CMS interoperability and prior authorization final rule, CMS-0057-F, binds Medicare Advantage organizations, Medicaid and CHIP fee-for-service and managed care plans, and qualified health plan issuers on the federally facilitated exchanges. Since 1 January 2026 those payers, exchange issuers excepted, have had to decide expedited requests within 72 hours and standard requests within seven calendar days. From 1 January 2027 they must run a Prior Authorization API reporting requirements, status and denial reasons. Drugs are excluded. For a lab this turns a phone-and-fax process into a dated one, and a late decision becomes evidence.
Where coverage rather than approval is the issue, the instrument is the Advance Beneficiary Notice of Noncoverage, form CMS-R-131. CMS gives labs the direct example: a research use only or investigational use only test is denied as not reasonable and necessary, so the beneficiary gets a notice (CMS MLN006266). Modifier GA reports a required notice on file, GX a voluntary one, GY a statutory exclusion, and GZ that none was issued, which denies automatically and leaves the patient owing nothing.
A molecular claim in California runs through a MolDX contractor and needs a registered Z-code. The same test billed in Texas does not. Our eligibility and prior authorization team sets the rule by jurisdiction at accessioning, not by trial and error at remittance.
A pathology charge should be provable from three independent records: the accession log, the signed final report, and the claim file. Most labs keep all three and reconcile none. We match them weekly, and cases in the first two but not the third are the largest recoverable number on this page. 2.4% of signed accessions had no charge in the billing file 30 days after sign-out (Luxen billing reviews). At 4,000 cases a month that is 96 cases read and reported for nothing.
Cases that do reach a claim can reach it late. Days to bill, from sign-out to submission, is AR you have already earned. It matters most at a year end, when a case signed in December and billed in February meets a reset deductible. Measure it weekly by referring client: the lag concentrates in two or three accounts whose requisitions arrive incomplete.
Enrollment is not paperwork, it is a date. A claim pays or denies on whether the rendering pathologist was effective with that payer on the date of service. Medicare lets physicians and their organizations bill for services provided 30 days before the effective enrollment date when circumstances precluded enrolling first, and 90 days where a Presidentially-declared disaster did (42 CFR 424.521). Commercial plans generally allow nothing. A pathologist who starts reading in March and is effective in June has produced three months of claims that will never pay.
The certificate is a claim field, not only a compliance object. An electronic claim for laboratory testing requires the performing and billing laboratory's CLIA number, plus the number of the lab that ran it where testing is referred out; on paper it goes in item 23 of the CMS-1500 (Claims Processing Manual, Chapter 16). A certificate that lapses quietly takes the claim file with it. Our credentialing team runs enrollment as a dated calendar, because a gap here looks exactly like a denial problem until someone checks effective dates.
A patient chooses a surgeon and a hospital. Nobody chooses a pathologist. That puts a standing share of a hospital-based group's commercial volume outside the network however well it contracts, and part of the AR is then governed by federal clocks rather than payer policy. Treated as a legal question it produces memos. Treated as a work queue it produces money.
The queue needs the date the bill went out, the date the initial payment or denial posted, and the date the negotiation window shuts. A plan owes the initial payment, or a denial, inside 30 calendar days of the bill. Open negotiation then runs 30 business days, and the window to start federal independent dispute resolution is the 4 business days after. Most groups miss the third date because the first payment posts like any other remittance.
The dispute process is not a coin flip. In the CMS federal IDR public use file covering July to December 2025, 1,372,563 disputes were filed, 1,449,900 were closed by certified IDR entities, and the initiating party, usually the provider, prevailed in roughly 85% of payment determinations (CMS federal IDR reports). Two consequences. First, the negotiation demand is worth making, because the credible alternative favors you. Second, batch: similar claims with the same payer can be disputed together, which is what makes the administrative fee rational on a pathology claim. We run this inside denials and AR recovery as a dated calendar per payer, so the demand goes out while the window is open.
We pulled every pathology claim in the Luxen claim audit (4,900 pathology claims out of 61,400 audited, January 2025 to June 2026) and every pathology and laboratory practice in the Luxen billing reviews (34 of 410 reviews, same period), counting what reached a claim, what was paid against contract, and how long approval took.
No competing page measures the first two, because both need the laboratory information system, not the claim file. A billing company that only sees claims cannot count the cases that never became one.
The group arrived with 58 days in AR, a first-pass denial rate of 15.6%, and $214,000 of AR older than 90 days untouched for a quarter. Out-of-network claims posted at the plan's first payment and closed there, and no remittance had met a contract in a year.
Over six months we matched the accession log to the claim file weekly, rebuilt the denial queue by root cause and payer, put every out-of-network claim on a dated negotiation calendar, and loaded the contracted fee schedules. Days in AR fell to 34, first-pass denial rate to 5.9%. We recovered $184,000 from the aged AR and $37,000 in underpayments. Reported by the practice administrator at the six-month review (Luxen client data).
Basis: 4,000 signed accessions a month at $92 net, $368,000 a month, $4,416,000 a year.
Recurring recovery of $83,904 plus $71,136 is $155,040, which alone does not cover a $198,720 fee. The fee also replaces something: at 8.8% of collections, billing this volume in house costs $388,608, so outsourcing saves $189,888. Net first-year effect is $344,928, plus $254,079 released once. Rerun it with your own case count.
Want this arithmetic run on your own collections and denial rate?
Run my numbersPathology revenue cycle management here is priced at 3% to 6% of collections, month to month, 30 days notice, nothing charged to start or leave. A lab collecting $368,000 a month pays $11,040 to $22,080.
Included at every level: eligibility and approval, certified coding, claim scrubbing and submission, payment posting, denials and appeals, underpayment recovery, patient statements, and monthly reporting by payer, referring client and specimen source. See what full-service medical billing covers.
Costed for a group collecting $250,000 a month, $3,000,000 a year. In-house figures are fully loaded.
| Line item | In-house | Luxen |
|---|---|---|
| Billing and AR staff, 2.5 FTE fully loaded | $155,000 a year | Included |
| Certified anatomic and clinical pathology coding | $75,000 a year | Included |
| Billing module seats and clearinghouse fees | $21,000 a year | Included |
| Denial rework and appeals | Absorbed by the same staff | Separate queue, owned by name |
| Credentialing and enrollment | $14,000 a year, or unmanaged | Included on request |
| Cover when someone leaves | Work stops or backs up | Continues, team based |
| Total | $265,000 a year, 8.8% of collections | $90,000 to $180,000 a year, 3% to 6% |
Keep it in house when one biller holds your whole payer mix, molecular volume is small, and AR over 90 days is under 15%. Move it when that AR climbs, when the biller is a single point of failure, or when molecular work outgrows whoever handles approvals. Compare medical billing companies first.
The question people search is which are the best RCM companies. Wrong question: the answer moves with your setting, bill-to mix and molecular volume. Score every candidate, this one included, on six weighted criteria.
| Criterion | What to ask for | Weight |
|---|---|---|
| Accession reconciliation | A written method for matching accession log, signed report and claim file, plus a sample exception report | 25 |
| Molecular approval | Named staff, median turnaround in business days, and the payer portals they hold credentials for | 20 |
| Component and bill-to routing | How global, professional-only and client-bill are decided per accession, and who catches a hospital patient | 15 |
| Underpayment detection | Whether paid amounts are checked against the loaded fee schedule on every remittance | 15 |
| Denial reporting | Denials by reason, payer and referring client, monthly, in writing, without asking | 15 |
| Contract terms | Fee basis in writing, notice period, setup and exit fees, who owns the data if you leave | 10 |
Ask for two references in your own setting: strength in clinical laboratory work does not transfer to anatomic pathology. 52% of practices that switched billing vendors cited missing denial reporting as the main reason (Luxen Practice Manager Survey 2026).
You already have someone doing this, so the question is what the changeover costs. It need not cost a gap.
A BAA is signed before anyone sees data. We take user access to the systems you already run and work claims inside them, so nothing migrates and your team learns no new software. Working claims start about two weeks after the BAA, first recovered payments about three weeks in. Oldest claims go first, because filing limits close and a redetermination must be filed within 120 calendar days of receiving the initial determination (42 CFR 405.942). Run both in parallel for a month if you want: your incumbent keeps the existing AR, we take new accessions from a stated date, and you compare denial rates on the same payers. 34% of practice managers replaced a biller in the past two years (Luxen Practice Manager Survey 2026).
Pathology billing lives behind the laboratory information system, not a clinic EHR, so we take user access under your BAA to the AP system, its billing module, the clearinghouse and the payer portals. Nothing migrates. Referring-practice orders arrive by interface, which is exactly where charge data goes missing.
Approval work comes last: it is judgment work, and the payer APIs that will carry it are not required until 1 January 2027.
Payer enrollment and client setup, order and eligibility, authorization and medical necessity, accessioning and charge capture, coding and claim submission, payment posting and underpayment review, then denials, appeals and patient balances. Three close before the pathologist signs the case out, which is why a claim-side fix never holds.
Score candidates against criteria rather than ranking brands, because the answer moves with your setting and molecular volume. Weight accession reconciliation at 25, molecular approval at 20, bill-to routing at 15, underpayment detection at 15, denial reporting at 15 and contract terms at 10. Weight reporting heavily: it is the top reason practices switch vendors.
Original Medicare runs no prior authorization program covering anatomic pathology or clinical laboratory services, and the WISeR model that began in January 2026 includes none of them. Commercial plans do authorize molecular and genetic testing, often through a separate vendor, taking a median 11 business days (Luxen claim audit).
Luxen prices it at 3% to 6% of collections, month to month, with nothing charged to start or to leave. A lab collecting $368,000 a month pays $11,040 to $22,080. Billing the same volume in house runs 7% to 9% of collections once salaries, benefits, software and clearinghouse fees are counted (Luxen billing reviews).
Working claims start about two weeks after a signed BAA, first recovered payments about three weeks in. Clean claim rate rose from 89.6% to 97.3% in the first 90 days and median days in AR dropped from 54 to 33 within 120 days (Luxen client data). Oldest claims go first, because filing limits and the 120 calendar day redetermination window close.
Billing is the claim: code the case, submit it, post the payment. Revenue cycle management owns both sides of it, from payer enrollment and eligibility before the specimen is grossed to underpayment recovery long after the money lands. 2.4% of signed accessions never reached a claim at all (Luxen billing reviews), and no claim-side process can find those.
A free 30 minute review of your AR ageing and denial reasons. We tell you what is recoverable and what it would take. No deck, no commitment, no fee.
Book a free revenue cycle assessment%20(1).avif)
